All In Biotech

Investigational drug · Phase 3

JNJ-81201887

Also called: AAVCAGsCD59

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Geographic Atrophy, Macular Degeneration.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

2

Any phase or sponsor naming "JNJ-81201887"

First trial start

2023

Mar 6, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "JNJ-81201887", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Geographic Atrophy
  • Macular Degeneration

Approved drugs for the same conditions: Wet macular degeneration · Geographic atrophy · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "JNJ-81201887" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Geographic Atrophy

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.